Inspire Medical Systems develops and commercializes minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. Its proprietary Inspire therapy is approved by the FDA, EU MDR and PDMA for moderate to severe obstructive sleep apnea, and product updates include the Inspire V system.
Company news commonly covers quarterly and annual results, revenue guidance, cash flow, earnings measures, reimbursement and coding developments, product launch activity, regulatory clearances such as MRI compatibility, executive changes and healthcare conference presentations.
Inspire Medical Systems, a medical technology company specializing in innovative, minimally invasive solutions for obstructive sleep apnea, announced its participation in the Jefferies Global Healthcare Conference. Scheduled for June 6, 2024, at 11:30 a.m. Eastern Time, the presentation will be accessible via a live webcast with a replay available for two weeks on Inspire’s Investor website.
Inspire Medical Systems, Inc. reported a 28% year-over-year revenue growth in the first quarter of 2024, reaching $164.0 million. The company expects profitability for the full year 2024, increasing revenue guidance to $783 million to $793 million, reflecting growth of 25% to 27% over 2023. With improved outlook and strong performance, Inspire is optimistic about the remainder of 2024.
Inspire Medical Systems, a medical technology company specializing in solutions for obstructive sleep apnea, will present at the BofA Securities 2024 Health Care Conference on May 14, 2024. The presentation will be live-streamed and available for replay on Inspire's Investor website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.